JunHe acted as the exclusive counsel for Worg Pharmaceuticals (Zhejiang) Co., Ltd. (“Worg” or the “ Company”) and assisted it in completing a series D financing round totaling hundreds of millions of RMB (the “Deal”). As Worg’s counsel, JunHe provided comprehensive legal services throughout this Deal. This financing round saw participation from notable investors including PICC Capital Equity Investment, Tsing Song Capital, and an undisclosed renowned industry investment institution.
Worg is a biopharmaceutical company focusing on delivering transformative immunotherapies to combat allergic, autoimmune diseases and other indications. The Company operates a wholly-owned subsidiary in Europe that integrates production, research and sales, and it boasts a portfolio of dozens of commercialized products. Worg is actively expanding its global footprint and advancing the clinical development and commercialization of innovative allergy immunotherapy products that are already listed in Europe. The establishment of new technology platforms PCFiT™ and Apitope® has enabled Worg to rapidly build a research and development pipeline targeting allergy and autoimmune disease indications. The Company has made significant strides in clinical trials, with its grass pollen allergy and Graves’ disease pipelines now in Phase II and III, respectively, across various countries worldwide. Following the completion of this Deal, Worg will accelerate the development and promotion of internationally leading allergy immunotherapies and precision diagnostic solutions in China, benefiting nearly 200 million allergy sufferers in the country.
This Deal took six months from initiation to closing. The deal team conducted multiple rounds of communication, discussion and coordination with investors on transaction structuring, agreement drafts, and closing arrangements. Leveraging its extensive experience in financing transactions and providing professional, meticulous legal services, JunHe assisted the Company in completing the signing and closing and will continue to provide ongoing support to the Company.
Partner JIANG, Wenjun (Kelvin) led this deal.